Aclaris Therapeutics Inc (NASDAQ: ACRS) is 133.33% higher on its value in year-to-date trading and has touched a low of $0.59 and a high of $5.64 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ACRS stock was last observed hovering at around $2.26 in the last trading session, with the day’s gains setting it 0.19%.
Currently trading at $2.45, the stock is 53.51% and 82.78% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.01 million and changing 8.41% at the moment leaves the stock 97.26% off its SMA200. ACRS registered -54.80% loss for a year compared to 6-month loss of 100.00%. The firm has a 50-day simple moving average (SMA 50) of $1.3154 and a 200-day simple moving average (SMA200) of $1.23605.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 109.40% gain in the last 1 month and extending the period to 3 months gives it a 111.21%, and is 35.36% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 11.36% over the week and 8.20% over the month.
Aclaris Therapeutics Inc (ACRS) has around 91 employees, a market worth around $174.80M and $27.08M in sales. Profit margin for the company is -136.65%. Distance from 52-week low is 315.11% and -56.56% from its 52-week high. The company has generated returns on investments over the last 12 months (-27.95%).
The EPS is expected to grow by 52.19% this year
121.0 institutions hold shares in Aclaris Therapeutics Inc (ACRS), with institutional investors hold 79.94% of the company’s shares. The shares outstanding are 70.89M, and float is at 67.49M with Short Float at 2.06%. Institutions hold 77.82% of the Float.
The top institutional shareholder in the company is BML CAPITAL MANAGEMENT, LLC with over 12.99 million shares valued at $14.29 million. The investor’s holdings represent 18.2739 of the ACRS Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 4.69 million shares valued at $5.16 million to account for 6.5952 of the shares outstanding. The other top investors are MILLENNIUM MANAGEMENT LLC which holds 3.34 million shares representing 4.6948 and valued at over $3.67 million, while D. E. SHAW & CO., INC. holds 4.6714 of the shares totaling 3.32 million with a market value of $3.65 million.
Aclaris Therapeutics Inc (ACRS) Insider Activity
The most recent transaction is an insider purchase by Leonard Braden Michael, the company’s 10% Owner. SEC filings show that Leonard Braden Michael bought 206,025 shares of the company’s common stock on Aug 05 ’24 at a price of $1.24 per share for a total of $0.26 million. Following the purchase, the insider now owns 14.25 million shares.
Aclaris Therapeutics Inc disclosed in a document filed with the SEC on Aug 02 ’24 that Leonard Braden Michael (10% Owner) bought a total of 167,544 shares of the company’s common stock. The trade occurred on Aug 02 ’24 and was made at $1.29 per share for $0.22 million. Following the transaction, the insider now directly holds 14.04 million shares of the ACRS stock.
Still, SEC filings show that on Jul 30 ’24, Leonard Braden Michael (10% Owner) acquired 173,730 shares at an average price of $1.30 for $0.23 million. The insider now directly holds 13,776,421 shares of Aclaris Therapeutics Inc (ACRS).
